メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・腎泌尿器外科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(13)
研究成果
(236)
フィンガープリント
医学部・腎泌尿器外科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Transitional Cell Carcinoma
100%
Overall Survival
91%
Partial Nephrectomy
82%
Prostate Cancer
73%
Kidney Transplantation
64%
Robot-Assisted Prostatectomy
60%
Pembrolizumab
59%
Heart Death
57%
Cystectomy
54%
Neoplasm
51%
Clear Cell Renal Cell Carcinoma
47%
Delayed Graft Function
37%
Prognostic Factor
35%
Progression Free Survival
33%
Pancreas Transplantation
32%
Retrospective Study
30%
Continence
28%
Recurrence Free Survival
27%
Kidney Tumour
26%
Multivariate Analysis
25%
Castration Resistant Prostate Cancer
25%
Cancer Specific Survival
23%
Nephroureterectomy
23%
Kidney Metastasis
22%
Brachytherapy
22%
Nivolumab
22%
Enfortumab Vedotin
22%
Prostate Specific Antigen
22%
Bleeding
22%
Transplantation
22%
Urinary Diversion
21%
Heart Muscle Ischemia
21%
Surgical Margin
20%
Recurrent Disease
20%
Graft Survival
20%
Biological Marker
20%
Bladder Cancer
18%
Operation Duration
18%
Neoadjuvant Chemotherapy
18%
Retroperitoneal Lymph Node Dissection
17%
Da Vinci Surgical System
17%
Kidney Function
16%
Progressive Disease
16%
Long Term Survival
16%
Urinary System
16%
High Risk Population
16%
Survival Rate
16%
Disease
15%
Postoperative Ileus
15%
Programmed Death-Ligand 1
15%
Kidney Graft
15%
Prospective Study
15%
Neutrophil Gelatinase Associated Lipocalin
14%
Immune-Related Adverse Events
14%
Extracorporeal
14%
Contrast-Enhanced Ultrasound
14%
Iodine 125
14%
Cadaver
14%
Combination Therapy
14%
Brain Death
14%
Clinical Trial
14%
Geriatrics
12%
Ischemia
12%
Propensity Score Matching
12%
Neutrophil
12%
Urine Incontinence
12%
Body Mass Index
11%
Glomerular Filtration Rate
11%
Enucleation
11%
Cisplatin
11%
Ileal Conduit
11%
Urine Cytology
10%
Tyrosine-Kinase Inhibitor
10%
Graft Failure
10%
C Reactive Protein
10%
Abiraterone
10%
Enzalutamide
10%
Radical Nephrectomy
10%
Provocation Test
10%
Glucagon
10%
Gemcitabine
10%
Androgen Receptor
10%
Nephrectomy
10%
Adverse Event
10%
Insulin Release
9%
Magnetic Resonance Imaging
9%
C-Peptide
9%
Holmium
9%
Lymphocyte
9%
Chemoradiation Therapy
9%
Avelumab
9%
Prostate Adenocarcinoma
9%
Liver Metastasis
9%
Kidney Allograft
8%
Bicalutamide
8%
Endocrine Function
8%
Acute Tubular Necrosis
8%
Sacrocolpopexy
8%
Abiraterone Acetate
8%
Robot-Assisted Surgery
8%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
99%
Castration Resistant Prostate Cancer
59%
Renal Cell Carcinoma
54%
Pembrolizumab
53%
Transitional Cell Carcinoma
48%
Prostate Cancer
46%
Heart Death
44%
Kidney Metastasis
39%
Progression Free Survival
34%
Adverse Event
32%
Malignant Neoplasm
32%
Androgen Receptor
31%
Delayed Graft Function
31%
Nivolumab
30%
Prostate Specific Antigen
28%
Chemotherapy
28%
Disease
25%
Bladder Cancer
24%
Biological Marker
23%
Enzalutamide
20%
Neoplasm
20%
Survival Rate
17%
Immune Checkpoint Inhibitor
16%
Abiraterone Acetate
16%
C Reactive Protein
16%
Combination Therapy
16%
Gemcitabine
15%
Docetaxel
14%
Neutrophil Gelatinase Associated Lipocalin
14%
Cabazitaxel
14%
Ipilimumab
14%
Cadaver
14%
Enfortumab Vedotin
14%
Cisplatin
13%
Cancer Specific Survival
12%
Abiraterone
11%
Protein Tyrosine Kinase Inhibitor
11%
Androgen
10%
Recurrence Free Survival
10%
Liver Metastasis
9%
Chemoradiation Therapy
9%
Sunitinib
9%
Sorafenib
9%
Immunotherapy
8%
Diseases
8%
Disease Exacerbation
8%
Prednisone
8%
Survival Prediction
8%
Vesicoureteral Reflux
8%
Everolimus
8%
Retrospective Study
7%
Urinary Tract Infection
7%
Posttransplant Lymphoproliferative Disease
7%
Standardized Incidence Ratio
7%
Recurrence Risk
7%
Heat Shock Protein 27
7%
Lymph Node Metastasis
7%
Holmium
7%
Racemase
7%
Vascular Disease
7%
Biochemical Recurrence
7%
Bacteriophage
7%
Cancer Antibody
7%
Rat Model
7%
Thrombocytopenia
7%
Brain Disease
7%
Tryptophan 2,3 Dioxygenase
7%
Pyelonephritis
7%
Nocturia
7%
Prostate Carcinoma
7%
Anticarcinogen
7%
Implant
7%
Ciclosporin
7%
Metastatic Colorectal Cancer
7%
Muscle Invasive Bladder Cancer
7%
Olaparib
7%
Tissue Inhibitor of Metalloproteinase 1
7%
Rectal Administration
7%
Flavoxate
7%
Complement Component C5
7%
Pharmacokinetics
7%
Immunoglobulin
7%
Recurrent Disease
7%
Clinical Trial
6%
Apalutamide
6%
Acid Phosphatase Prostate Isoenzyme
5%
Graft Failure
5%
Indoleamine 2,3 Dioxygenase
5%
Keyphrases
Pembrolizumab
29%
Overall Survival
29%
Metastatic Urothelial Carcinoma
20%
Organ Recovery
14%
Robot-assisted Radical Prostatectomy
14%
Neutrophillymphocyte Ratio
14%
Kidney Transplantation
14%
Delayed Graft Function
14%
Donation after Cardiac Death
14%
Prostate Cancer
14%
High-grade Urothelial Carcinoma
14%
Japanese Patients
14%
Postoperative Day
9%
Partial Nephrectomy
9%
Multi-institutional
9%
Bicalutamide
8%
Bladder Injury
8%
Objective Response Rate
8%
Poor Prognosis
8%
Prospective multi-institutional Study
7%
Software Analysis
7%
Renal Hilar Tumor
7%
Flow Obstruction
7%
Urinary Tract Infection
7%
Pathologic
7%
Innovative System
7%
Outlet Obstruction
7%
Escherichia Coli Isolates
7%
Total Cell-free DNA
7%
Bladder Metastasis
7%
Robotic Partial Nephrectomy
7%
Dysmetabolism
7%
C-X-C Chemokine Receptor Type 4 (CXCR4)
7%
Deep Ensemble
7%
Robot-assisted Radical Nephrectomy
7%
Prognostic Value
7%
Prostate-specific Antigen Response
7%
Ensemble Machine Learning
7%
Type I Diabetes
7%
Inferior Vena Cava Thrombectomy
7%
Glucagon Stimulation Test
7%
Testicular Epidermoid Cyst
7%
Pentafecta Outcomes
7%
Japanese Studies
7%
Alkaline Phosphatase
7%
Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL)
7%
Type I Procollagen
7%
Prostate Brachytherapy
7%
Linked Seeds
7%
Isograft
7%
Renal Autotransplantation
7%
Loose Seeds
7%
Human NK Cells
7%
HLA-E
7%
Urethral Suspension
7%
CD94
7%
NKG2
7%
Trifecta Outcomes
7%
Selective Clamping
7%
Regulatory T Cells
7%
Nephron Sparing
7%
Ureteroscopic Surgery
7%
Enhanced Recovery Program
7%
Immunological Risk
7%
Robotic Surgery
7%
Trifecta
7%
Antibody Phage Library
7%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
7%
Anti-cancer Antibody
7%
Spermatic Cord
7%
Computed Tomography
7%
Premature Termination Codon
7%
Collaborative Study
7%
Pyonephrosis
7%
Japan
7%
Metastatic Renal Cell Carcinoma (mRCC)
7%
Islet Xenograft
7%
Upper Urinary Tract Infection
7%
Robot-assisted Laparoscopic Partial Nephrectomy
7%
RNA Kinetics
7%
Localized Kidney Cancer
7%
Surgical Systems
7%
Bladder Eversion
7%
Real-world Application
7%
Nationwide Surveillance
7%
Pediatric
7%
Mycobacterium Tuberculosis Infection
7%
Structure Ratio
7%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
7%
Nephroureterectomy
7%
Upper Tract Urothelial Carcinoma
7%
Prognostic Impact
7%
Immune-related Adverse Events
7%
Microvascular Invasion
7%
Female Stress Urinary Incontinence
7%
Infiltration
7%
Influence Maintenance
7%
Pancreatic Transplantation
7%
Clinical Kidney Transplantation
7%
High-grade Prostate Cancer
7%